Dr. Linda Vahdat and her colleagues are very excited to be involved in the development of glembatumuma vedotin as it has the potential to be among the very first drugs for triple negative breast cancer.
http://jco.ascopubs.org/content/early/2014/09/29/JCO.2013.52.5683.full.pdf+html